Anti-SIRPα antibody

MYPI2025001876A0Undetermined Publication Date: 2020-01-10DAIICHI SANKYO CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025001876
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-07-10
Filing Date
2019-07-09
Publication Date
2020-01-10
Patent Text Reader

Abstract

The object of the present invention is to provide an anti-SIRP antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. The present invention is an antibody that binds specifically to human SIRP to inhibit binding of human SIRP to CD47, the antibody comprising: (a) a light chain CDRL1 consisting of an amino acid sequence set forth in SEQ ID NO: 1; (b) a light chain CDRL2 consisting of an amino acid sequence set forth in SEQ ID NO: 2; (c) a light chain CDRL3 consisting of an amino acid sequence set forth in SEQ ID NO: 3; (d) a heavy chain CDRH1 consisting of an amino acid sequence set forth in SEQ ID NO: 4; (e) a heavy chain CDRH2 consisting of an amino acid sequence set forth in SEQ ID NO: 5; and (f) a heavy chain CDRH3 consisting of an amino acid sequence set forth in SEQ ID NO: 6, wherein a heavy chain constant region is a heavy chain constant region of human IgG4, and phenylalanine at position 234, as numbered according to the EU index as in Kabat et al., is substituted by alanine, leucine at position 235 is substituted by alanine, and serine at position 228 is substituted by proline. (Fig. 1)
Need to check novelty before this filing date? Find Prior Art